expert perspectives

in Chronic Myeloid Leukemia

Expert Perspectives in Chronic Myeloid Leukemia to Cover Key Topics in Chronic Myeloid Leukemia Treatment

Overview

Expert Perspectives delivers health care providers with insights from key thought leaders on the latest advancements and current practices in medicine, in a concise and timely format. This issue of Expert Perspectives in Chronic Myeloid Leukemia will feature selected topics in Chronic Myeloid Leukemia that we hope you will find of value in your clinical practice.

The clinicians who were surveyed selected the following experts and topics.

Community-Selected Experts: 

Gabriela S. Hobbs, MD

Assistant Professor, Medicine
Harvard Medical School
Clinical Director, Leukemia
Massachusetts General Hospital
Boston, MA

Mark J. Levis, MD, PhD

Director, Adult Leukemia Service
Co-Division Director, Hematologic Malignancies
Professor of Oncology
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, MD

Neil P. Shah, MD, PhD

Edward S. Ageno Distinguished Professorship in Hematology/Oncology
Professor, Department of Medicine
Program Leader, Hematopoietic Malignancies Program
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA 


Community-Selected Topics: 

Expert Roundtables 

    Effectiveness of Treatments for Chronic Myeloid Leukemia: Raising the Bar
    Initial Approach to Newly Diagnosed Patients With Chronic Myeloid Leukemia
    Chronic Myeloid Leukemia: Current Recommendations for Treatment and Monitoring
    Risk Stratification and Current Challenges in Chronic Myeloid Leukemia

Clinical Topic Updates 

    Next-Generation Sequencing–Detectable Mutations in Chronic Myeloid Leukemia
    Cardiovascular Side Effects With Available Tyrosine Kinase Inhibitors
    Chronic Myeloid Leukemia: Advances in Molecular Monitoring
    Immune Recovery and Treatment-Free Remission in Chronic Myeloid Leukemia

Patient Care Perspectives 

    COVID-19 and Impacts in Patients With Chronic Myeloid Leukemia
    Next Steps After Inadequate Response to Established Tyrosine Kinase Inhibitors
    Recommendations for Second-Generation Tyrosine Kinase Inhibitors as Frontline Therapy
    Prognostic Scores in Chronic Myeloid Leukemia: Points for Patient Discussion

More in Chronic Myeloid Leukemia

Thumb

Chronic Myeloid Leukemia

Next-Generation Sequencing–Detectable Mutations in Chronic Myeloid Leukemia

Clinical Topic Updates by Gabriela S. Hobbs, MD

Although upfront testing with next-generation sequencing (NGS) for BCR-ABL1 kinase domain mutations is not currently standard, the science of mutat...READ MORE

Thumb

Chronic Myeloid Leukemia

COVID-19 and Impacts in Patients With Chronic Myeloid Leukemia

Patient Care Perspectives by Gabriela S. Hobbs, MD

The COVID-19 pandemic has challenged clinical care, particularly for patients with chronic myeloid leukemia (CML). The increased uptake of telemedi...READ MORE

Thumb

Chronic Myeloid Leukemia

Cardiovascular Side Effects of Available Tyrosine Kinase Inhibitors

Clinical Topic Updates by Mark J. Levis, MD, PhD

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML) to such an extent that this once-lethal disea...READ MORE

More In Oncology

MDS & AML

Emerging Immuno Myeloid Therapies In Mds And Aml

Expert Roundtables by Andrew M. Brunner, MD; Courtney D. DiNardo, MD, MSCE; and Rami S. Komrokji, MD

MDS & AML

Improving Response Durability In High Risk Mds And Aml

Expert Roundtables by Andrew M. Brunner, MD; Courtney D. DiNardo, MD, MSCE; and Rami S. Komrokji, MD

MDS & AML

Integrating Genomics Into The Classification And Management Of Mds

Expert Roundtables by Andrew M. Brunner, MD; Courtney D. DiNardo, MD, MSCE; and Rami S. Komrokji, MD